AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist.
The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. Located in Switzerland, AL-S Pharma has the single aim of developing a drug candidate for amyotrophic lateral sclerosis (ALS).
The giant Eli Lilly is also contributing through Chorus, a division directed to advance drug candidates using cost-effective clinical strategies. If everything goes as planned, Chorus will step in in 2018, when the first human study of AL-S’ candidate is projected to begin.
The drug candidate, AP-101, is a human monoclonal antibody that targets misfolded SOD1 proteins that cause ALS. It was generated and validated in pre-clinical models by Neurimmune’s Reverse Translational Medicine platform. This technology uses high-throughput analysis of human immune responses to specific disease-related proteins in order to identify targets for therapeutic antibodies.